kilat 333KT-333 is the first heterobifunctional degrader against an undrugged transcription factor to enter clinical development. In November 2021, Kymera announced that multiple abstracts werePT Kilat Dotcom Indonesia Gedung Bali United, Lantai 3, Jl. Panjang No.29, RT.8RW.1, Kelurahan Kedoya Selatan, Kecamatan Kebon Jeruk, Kota